+44 (0) 1223 755950
+1 832 327 7413
Brolucizumab
REQUEST MORE INFO
Catalogue No: abx831334
Price:
US$464.00
(Size: 100 µg)
Reviews: 
(0 Publications and Reviews)
(0 Publications and Reviews)
Click on the image to see the image legend
Brolucizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting VEGFA, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Brolucizumab, also known as RTH258 or ESBA1008, 4 is a monoclonal antibody indicated to treat neovascular age related macular degeneration. Brolucizumab was granted FDA approval in October 2019. 6.
Research Articles on VEGFA
| Target | VEGFA |
| Clonality | Monoclonal |
| Reactivity | Human |
| Expression | Recombinant |
| Tested Applications | ELISA, WB |
| Host | Human |
| Recommended dilutions | Optimal dilutions/concentrations should be determined by the end user. |
| Conjugation | Unconjugated |
| Form | Liquid |
| Purity | > 95% |
| Purification | Purified from cell culture supernatants by Protein A/G chromatography. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Tag | scFv Kappa-heavy |
| Buffer | 0.01 M PBS. pH 7.4. |
| CAS Number | 1531589-13-5 |
| Concentration | Batch-dependent, typically between 0.5-2.0 mg/ml. |
| Availability | Shipped within 7-12 working days. |
| Note | This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use. |